NCT02618408Phase 3Completed

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)

Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2019-09-04Actual
Enrollment · participants333Actual
Source updated2024-01-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.